PDS BIOTECHNOLOGY CORP · Data as of 2026-09-08
2026
The topline survival results of the trial appear to confirm the potential efficacy of PDS0101 in HPV16-positive head and neck cancer treatment, and publication of the full results of the trial are expected in 2026.Source filing
2H 2026
PDS01ADC + HAIP Stage 1 Cholangiocarcinoma PDS01ADC + Enzalutamide vs Enzalutamide Biochemically Recurrent Prostate cancer PDS01ADC + Docetaxel Castration Resistant Prostate cancer Final Data ReadoutPDS01ADC + HAIP Colorectal cancer PDS0101 + CRT Phase 2 data publication Cervical cancer VERSATILE-003 (Head and neck cancer) 2Q 2026 PDS01ADC + HAIPPreliminary data publicationColorectal cancer16 Upcoming Catalysts CRT = Chemoradiotherapy PFS = Progression free survival PHASE 2 TRIALS 2H 2026 1H 2027 2H 2027 1Q 2026 PDS01ADC + docetaxel in metastatic castration resistant prostate cancerPreliminary data publication15 Adoption of Amended Protocol (FDA)Source filing